Jennifer Doudna - Johnson Johnson Independent Director

JNJ Stock  MXN 3,190  21.83  0.69%   

Director

Dr. Jennifer A Doudna, Ph.D., is the Independent Director of the Company. She has joined the faculty at University of California, Berkeley, as a Professor of Biochemistry Molecular Biology in 2002. She directs the Innovative Genomics Institute, a joint UC BerkeleyUC San Francisco center, holds the Li Ka Shing Chancellors Professorship in Biomedicine and Health, and is the chair of the Chancellors Advisory Committee on Biology at UC Berkeley. Dr. Doudna is Principal Investigator at the Doudna Lab at UC Berkeley and has founded and serves on the scientific advisory boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., both leading CRISPR genome engineering companies. She was an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Alan T. Waterman Award the Eli Lilly Award in Biological Chemistry of the American Chemical Society a corecipient of the Breakthrough Prize in Life Sciences a corecipient of the Gruber Prize in Genetics a corecipient of the Canada Gairdner International Award the Heineken Prize for Biochemistry and Biophysics the Tang Prize the Japan Prize and the Albany Medical Center Prize . Dr. Doudna was elected to the National Academy of Sciences the American Academy of Arts and Sciences the National Academy of Medicine the National Academy of Inventors and as a Foreign Member of the Royal Society . Dr. Doudna is a Trustee for Pomona College. since 2018.
Age 55
Tenure 6 years
Phone732 524 0400
Webhttps://www.jnj.com

Johnson Johnson Management Efficiency

The company has return on total asset (ROA) of 0.0881 % which means that it generated a profit of $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2414 %, meaning that it generated $0.2414 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.
Johnson Johnson has accumulated 29.98 B in total debt with debt to equity ratio (D/E) of 0.48, which is about average as compared to similar companies. Johnson Johnson has a current ratio of 1.36, which is within standard range for the sector. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

William EasterDelta Air Lines
70
CHRISTOPHER HAZLETONDelta Air Lines
51
Dan DingesUnited States Steel
65
John EngelUnited States Steel
57
Patricia DennisUnited States Steel
72
Jeanne JacksonDelta Air Lines
67
Murry GerberUnited States Steel
66
Patricia TraceyUnited States Steel
67
Stephen GirskyUnited States Steel
56
Enrique MejoradaSouthern Copper
62
Eugene SperlingUnited States Steel
60
Paul MascarenasUnited States Steel
57
Alfredo PerezSouthern Copper
65
Sergio RialDelta Air Lines
58
John FaraciUnited States Steel
69
Luis BonillaSouthern Copper
58
Rafael AnciolaSouthern Copper
57
Michael HuertaDelta Air Lines
62
Kathy WallerDelta Air Lines
60
David TaylorDelta Air Lines
61
Michael McGarryUnited States Steel
61
Johnson Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. Johnson Johnson was founded in 1886 and is based in New Brunswick, New Jersey. JOHNSON JOHNSON operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 136000 people. Johnson Johnson (JNJ) is traded on Mexican Exchange in Mexico and employs 39 people.

Management Performance

Johnson Johnson Leadership Team

Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
A Washington, Independent Director
Dirk Brinckman, Chief Officer
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Joseph CPA, Ex CFO
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Robert Decker, Controller Officer
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
James Swanson, Ex Officer
D Davis, Independent Director
Hubert Joly, Independent Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Jessica Moore, VP Relations
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Elizabeth Forminard, Exec Counsel
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Mark Weinberger, Independent Director

Johnson Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Johnson Stock Analysis

When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.